基于网络药理学及分子对接研究黄芪-白花蛇舌草药对治疗肾纤维化的作用机制OA
A study on the mechanism of couplet medicinals of Huang Qi and Baihua She She Cao in the treatment of renal fibrosis based on network pharmacology and molecular docking
目的:基于网络药理学及分子对接研究黄芪-白花蛇舌草治疗肾纤维化的关键靶点、药理作用及其机制.方法:通过网络药理学方法,运用 TCMSP 在线分析平台,获取黄芪、白花蛇舌草的活性成分和靶点,利用在线数据库 GeneCards 获得肾纤维化的相关基因,利用 Venny 2.1.0 软件获取疾病与药物交集靶点,将交集靶点导入 DAVID 数据库进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析,通过 STRING 数据库构建蛋白质-蛋白质相互作用靶点网络,Cytoscape 3.10.0软件构建药物-成分-靶点网络图,并筛选出前 10 个靶点,作为黄芪-白花蛇舌草治疗肾纤维化的重要靶点.将核心有效成分及重要靶点导入在线数据平台 CB-Dock2 进行分子对接验证,并运用 PyMOL 2.6 软件将分子对接结果可视化.结果:筛选出 17种化学成分、406 个靶点,重要靶点为肉瘤基因(sarcoma gene,SRC)、丝氨酸/苏氨酸蛋白激酶 1(akt serine/threonine kinase 1,AKT1)、磷脂酰肌醇-3-激酶催化亚基 α(phosphatidylinositol-3-kinase catalytic alpha polypeptide,PIK3CA)、信号转导与转录激活因子(signal transducer and activator of transcription,STAT)3等,通过GO 分析筛选得到生物学过程444个,主要涉及正向调节磷脂酰肌醇 3-激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶 B(Akt)信号转导、调节多细胞生物的发育,细胞组成 59 个和分子功能 128 个,通过 KEGG 分析筛选得到 159 条通路,其中,黄芪-白花蛇舌草治疗肾纤维化的主要信号通路为丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路、PI3K-Akt 信号通路、肿瘤坏死因子(tumor necrosis factor,TNF)信号通路、缺氧诱导因子(hypoxia-inducible factor-1,HIF-1)信号通路、Janus 激酶(Janus kinase,JAK)/STAT信号通路等.通过药理学方法研究黄芪-白花蛇舌草治疗肾纤维化的药理基础及机制,运用分子对接技术验证核心靶点与核心成分的亲和力,其中,华良姜素、异鼠李素、异黄烷酮、槲皮素与 PIK3CA 的亲和力较好.结论:黄芪-白花蛇舌草从调控多细胞生物的发育、抗炎性反应、抗氧化、调节胰岛素分泌等方面治疗肾纤维化,具有多靶点、多成分和多通路的药效特点,为肾纤维化的治疗提供新思路.
Objective:Based on network pharmacology and molecular docking,this investigation aims to analyze the important targets,pharmacological functions,and mechanisms of Huang Qi(Radix Astragali seu Hedysari)-Baihua She She Cao(Herba Hedyotis Diffusae)in the management of renal fibrosis(RF).Methods:Through network pharmacology methods,the TCMSP online analysis platform was used to obtain the active componts and targets of Huang Qi-Baihua She She Cao.The online database GeneCards was utilized to obtain RF related genes.The Venny 2.1.0 software was employed to acquire the intersection targets between the disease and the drugs.The intersecting targets were next introduced into the DAVID database to conduct GO and KEGG enrichment analyses.The STRING database was harnessed to build the protein-protein interaction target network,while the Cytoscape 3.10.0 software was employed for constructing the drug-ingredient-target network diagram.The top ten targets were screened out as the important targets of Huang Qi-Baihua She She Cao in treating RF.The molecular docking verification was carried out by importing the core active components and crucial targets into the online data platform CB-Dock2,and the PyMOL 2.6 software was employed to visualize the molecular docking.Results:A grand total of 17 chemical components and 406 targets were screened out.The important targets included SRC,AKT1,PIK3CA,etc.Through GO analysis,444 biological processes were screened out,mainly involving the positive regulation of PI3K-Akt signal transduction and the regulation of the development of multicellular organisms.There were 59 cellular components and 128 molecular functions.Through KEGG analysis,159 pathways were screened out.The main signaling pathways of Huang Qi-Baihua She She Cao in treating RF were MAPK signaling pathway,PI3K-Akt signaling pathway,TNF signaling pathway,etc.The pharmacological basis and mechanism of Huang Qi-Baihua She She Cao in treating RF were studied through pharmacological methods,and molecular docking technology was employed to validate the affinity between the core targets and core components.Among them,Jaranol,isorhamnetin,isoflavanone,and quercetin had good affinities with PIK3CA.Conclusion:Huang Qi-Baihua She She Cao couplet medicinals treats RF by regulating the development of multicellular organisms,anti-inflammation,anti-oxidation,and insulin secretion.Its pharmacological effects are marked by multi-target,multi-component,and multi-pathway properties,thus providing new insights into the treatment of RF.
王田田;卢晶晶;李正胜
贵州中医药大学,贵州 贵阳,550002贵州中医药大学第二附属医院,贵州 贵阳,550001贵州中医药大学第二附属医院,贵州 贵阳,550001
医药卫生
网络药理学分子对接黄芪白花蛇舌草肾纤维化
Network pharmacologyMolecular dockingHuang QiBaihua She She CaoRenal fibrosis
《中医临床研究》 2026 (1)
12-21,10
贵州中医药大学第二附属医院院内科研项目(GZEYK-B[2025]3号).
评论